The UK and US have announced a landmark bilateral deal that will preserve zero import taxes on British drug products going into the US market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to raise funding on medicines through the NHS. This commitment ensures that duties on these crucial goods will remain at zero for a duration of the next three years.
This deal comes after earlier threats to dramatically increase tariffs on patented drug imports, with figures discussed reaching 100%.
"This deal with the Britain strengthens the global environment for new treatments and brings long-overdue balance to transatlantic drug exports," an announcement declared.
Commercial Importance
Drugs are one of the UK's most significant goods shipped to the US, which is by far the largest market for major UK drugmakers.
Trade data show that in the 12 months to the end of last September, the UK exported drugs totaling over eleven billion pounds to the US. This amount accounted for nearly one-fifth of British export trade in that period.
"This deal protects work, boosts investment and sets the stage for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary remarked.
Specific NHS Changes
The agreement involves several specific pledges from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to increase overall public funding on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, rebates exceeded 20%.
Recent Tensions
The pact takes place against a long-running tension between the drug companies and the British authorities over medicine costs and regulatory access.
These tensions were exacerbated by assertions that American patients were charged significantly more for the same drugs than patients in the Britain and the EU.
Recently, several significant manufacturing plans in the UK have been paused or scrapped, while major investments have been directed toward US facilities.
One official stated that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a share of its resources over the past decade.
